Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


Pharmacology and Clinical Pharmacology of Methylarginines Used as Inhibitors of Nitric Oxide Synthases

Author(s): Anja Kittel and Renke Maas

Affiliation: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Fahrstraße 17, 91054 Erlangen, Germany.

Keywords: Asymmetric dimethylarginine (ADMA), Symmetric dimethylarginine (SDMA), Monomethylarginine (L-NMMA), Nitric oxide synthase (NOS), Dimethylarginine dimethylaminohydrolase (DDAH), Alanine-glyoxylate aminotransferase 2 (AGXT2).


The methylarginines asymmetric dimethylarginine (ADMA) and monomethylarginine (L-NMMA) are endogenously formed inhibitors of nitric oxide synthases (NOS), which have extensively been investigated as risk markers and used as pharmacological tools to study the L-arginine-nitric oxide (NO) pathway in vitro and in vivo. It is the aim of the present review to summarize the clinical and experimental data on the pharmacological properties that are of relevance when planning and conducting experiments and clinical studies involving methylarginines. Key pharmacodynamic and pharmacokinetic data including IC50 values of ADMA and L-NMMA for NOS isoforms and transport proteins, as well as metabolism by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) and alanine-glyoxylate aminotransferase 2 (AGXT2) are discussed.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [3530 - 3547]
Pages: 18
DOI: 10.2174/13816128113196660750